Motus GI Holdings, Inc. (MOTS) News
Filter MOTS News Items
MOTS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MOTS News Highlights
- For MOTS, its 30 day story count is now at 6.
- Over the past 20 days, the trend for MOTS's stories per day has been choppy and unclear. It has oscillated between 2 and 4.
- The most mentioned tickers in articles about MOTS are PURE, PRE and ACT.
Latest MOTS News From Around the Web
Below are the latest news stories about MOTUS GI HOLDINGS INC that investors may wish to consider to help them evaluate MOTS as an investment opportunity.
Motus GI Holdings Looks For Strategic AlternativesMotus GI Holdings Inc (NASDAQ: MOTS) has initiated a process to explore a range of strategic and financing alternatives. As part of this process, the company has engaged Lake Street Capital Markets LLC as an advisor. In addition, the board has approved a strategic restructuring program to preserve capital by initially reducing quarterly operating costs by approximately 35%. Motus plans to eliminate approximately 45% of its workforce, which is expected to be completed during the first quarter of |
Motus GI Announces Exploration of Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring PlanLake Street Capital Markets LLC engaged to act as an advisor to the CompanyBoard of Directors approved restructuring program with the objective of preserving capital to align with strategic process timelineManagement plans to continue providing sales and support for existing Pure-Vu EVS customers and pipeline opportunities in contracted health systemsCompany to move forward with regulatory process and commercial readiness for Pure-Vu EVS Gastro FORT LAUDERDALE, Fla., Jan. 10, 2023 (GLOBE NEWSWIR |
Motus GI Announces Improvement of Pure-Vu® EVS System for Use in Upper Gastrointestinal (GI) Bleeding Procedures Following Successful Pre-Clinical TestsFORT LAUDERDALE, Fla., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today provided an update on the development of its Pure-Vu ® EVS system compatible with gastroscopes used during upper gastrointestinal (GI) endoscopy procedures to remove blood, blood clots and debris in order to provide a clear field-of-view for the endoscopist. |
GOGL, CEI and BYSI are among pre market gainersMotus GI Holdings (MOTS) +33% announces improvement of Pure-Vu® EVS System for use in upper Gastrointestinal Bleeding Procedures Following Successful Pre-Clinical Tests.Laser… |
Motus GI Holdings Inc. (NASDAQ: MOTS) Stock Forecast For 2022: Increases Growth Prospects To $9 Per ShareIn the latest trading session, 1.51 million Motus GI Holdings Inc. (NASDAQ:MOTS) shares changed hands as the company’s beta touched 1.74. With the company’s most recent per share price at $1.03 changing hands around $0.01 or 0.99% at last look, the market valuation stands at $4.75M. MOTS’s current price is a discount, trading about -1162.14% … Motus GI Holdings Inc. (NASDAQ: MOTS) Stock Forecast For 2022: Increases Growth Prospects To $9 Per Share Read More » |
Motus GI Holdings Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagMotus GI Holdings ( NASDAQ:MOTS ) Third Quarter 2022 Results Key Financial Results Net loss: US$4.96m (loss widened by... |
Analysts Are Bullish on These Healthcare Stocks: Syros Pharmaceuticals (SYRS), Motus Gi Holdings (MOTS)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Syros Pharmaceuticals (SYRS – Research Report), Motus Gi Holdings (MOTS – Research Report) and TransCode Therapeutics (RNAZ – Research Report) with bullish sentiments. Syros Pharmaceuticals (SYRS) H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Syros Pharmaceuticals today and set a price target of $20.00. The company's shares closed last Monday at $3.66, close to its 52-week low of $3.52. According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -28.1% and a 24.4% success rate. |
Motus GI Holdings, Inc. (MOTS) Reports Q3 Loss, Misses Revenue EstimatesMotus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 9.63% and 14.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Motus GI Reports Third Quarter 2022 Financial Results and Provides Business UpdateFORT LAUDERDALE, Fla., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the third quarter ended September 30, 2022 and provided a corporate update. |
Motus GI Holdings, Inc. (MOTS) Q3 2022 Earnings Call TranscriptMotus GI Holdings, Inc. (NASDAQ:NASDAQ:MOTS) Q3 2022 Earnings Conference Call November 14, 2022 04:30 PM ET Company Participants Garth Russell - Managing Director-LifeSci Advisors, LLC Tim… |